Delivery Order SPE2DB20D9331-SPE2DB25FL1R5
- Not listed
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth up to $25,529.76 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of 4563969889 - Perjeta 420 mg/14 ml vial, 14 ml, with a performance period through April 1, 2024. This delivery order is issued under DMS Pharmaceutical Group's indefinite delivery contract SPE2DB24FSW68 with DLA, which has a ceiling value of up to...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $27,343.62 on July 28, 2025, for the supply of Perjeta 420 mg/14 mL vials. The contract, which carries no set-aside designation, is funded by the Defense Logistics Agency's Medical Supply Chain and is scheduled for completion by August 18, 2025. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract, valued at $8,509.92, to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of the oncology drug Perjeta (pertuzumab) 420 mg/14 mL vial, with an ultimate completion date of October 10, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the...
- This federal contract award is a delivery order valued at $13,671.78 issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of Perjeta, a 420 mg/14 ml vial medication, with a period of performance through April 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $54.7K by the Defense Logistics Agency for the supply of Perjeta 420 mg/14 mL vials. The contract, awarded on July 30, 2025, represents a firm fixed-price delivery order with an ultimate completion date of August 20, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $34,039.68, is for the delivery of Perjeta 420 mg/14 ml vial, a branded oncology medication, with a performance period ending on July 3, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $17,019.84 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of 4563691587 PERJETA 420 MG/14 ML VIAL 14ML pharmaceutical products. This order is placed under DMS Pharmaceutical Group's existing indefinite delivery contract 4600082013 with DLA, which has a potential value of up to $4,999,999 and enables the agency to...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $34,039.68 firm fixed-price delivery order is for the supply of Perjeta 420 mg/14 ml vials, with a period of performance through October 30, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999,...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,756.60 firm fixed-price delivery order is for the supply of the prescription drug Perjeta (420 mg/14 ml vial, 14 ml) to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the...
- This federal contract award, valued at $7,859.80, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of Perjeta, a 420 mg/14 ml vial medication, with a completion date of December 19, 2022. DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued...
- SPE2DB20D9331Indefinite Delivery Contract
- SPE2DB20D9331-SPE2DB25FL1R5Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $63,801.78 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, awarded on August 7, 2025, with an ultimate completion date of August 28, 2025, represents a specific supply requirement fulfilled under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA. The contract carries no set-aside designation, allowing the vendor to compete on the open market while leveraging its status as a woman-owned small business. DMS Pharmaceutical Group is established as a critical supplier within the federal pharmaceutical supply chain, distributing prescription medications, biologics, and medical consumables to Department of Defense healthcare facilities nationwide. The company's primary vehicle with DLA—the SPE2DB Indefinite Delivery Contract valued at $499,999,999 through November 2026—enables the issuance of delivery orders for an extensive pharmaceutical portfolio supporting military health facility operations worldwide. This delivery order for Perjeta, an oncology treatment medication, exemplifies the company's role in supplying specialized pharmaceutical products essential to military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $63.8k | 8/7/25 |